Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –
Novartis YoY Growth in the U.S.: 35.0% in FY2025, down 8.0 pts from a year earlier.
Latest, FY2025
35.0%
Period ended Dec 31, 2025
Change on a year earlier
-8.0 pts
43.0% in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Kesimpta | Neuroscience | Relapsing forms of multiple sclerosis (MS) | 2 943 | 35 | 1 483 | 42 | 39 | 4 426 | 37 | 36”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | YoY Growth in the U.S. (% USD / cc) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 35.0% | -8.0 pts | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 43.0% | -23.0 pts | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2023 | Dec 31, 2023 | 66.0% | -99.0 pts | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2022 | Dec 31, 2022 | 165.0% | – | Novartis Form 6-K (0001370368-23-000008) ↗ |
Cite this data
StockData. (2026). Novartis YoY Growth in the U.S. (%), annual FY2022–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-kesimpta-us-yoy-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.